Mycophenolate Mofetil Side Effects and Monitoring

Introduction to Side Effects

• Mycophenolate mofetil has numerous side effects affecting multiple organ systems, with gastrointestinal effects, hematologic abnormalities, and increased risk of infections being the most common and clinically significant adverse reactions, as reported by the American Thoracic Society 1, 2

Major Side Effect Categories

• Nausea, anorexia, vomiting, dyspepsia, abdominal pain, diarrhea, and constipation are common gastrointestinal effects 1
• Anemia, leukopenia, thrombocytopenia, and rarely pure red cell aplasia are hematologic effects, according to the American Society of Hematology 1, 3
• Increased risk of opportunistic infections due to immunosuppression is a significant concern, as noted by the Infectious Diseases Society of America 1, 2
• Systemic hypertension, peripheral edema, and tachycardia are cardiovascular effects, as reported by the American Heart Association 1
• Rash and increased risk of skin neoplasms are dermatologic effects, according to the American Academy of Dermatology 1
• Headache, tremor, insomnia, dizziness, and anxiety are neurologic effects, as noted by the American Academy of Neurology 1
• Hyperglycemia, hypercholesterolemia, electrolyte abnormalities, Cushingoid changes, and hirsutism are metabolic/endocrine effects, as reported by the Endocrine Society 1
• Urinary tract infections, hematuria, tubular necrosis, urinary frequency, burning on urination, kidney stones, and vaginal burning and bleeding are genitourinary effects, according to the American Urological Association 1
• Increased cough, dyspnea, respiratory infections, risk of pneumonitis, and fibrosis are respiratory effects, as noted by the American Thoracic Society 1
• Bone pain, leg cramps, myalgias, and hand cramps are musculoskeletal effects, as reported by the American College of Rheumatology 1

Pregnancy Risks

• FDA black box warning for use during pregnancy due to teratogenic and embryocidal effects, as classified by the FDA 2, 4
• Severe cranial, facial, and cardiac abnormalities have been reported in neonates, according to the Teratology Society 5

Drug Interactions

• Absorption is inhibited by activated charcoal, aluminum/magnesium salts, cholestyramine, colesevelam, colestipol, and iron, as reported by the American Society of Clinical Pharmacology 2
• Coadministration with azathioprine may increase purine metabolism inhibition, according to the National Kidney Foundation 2
• Increases plasma concentration of acyclovir or ganciclovir, especially with renal impairment, as noted by the Infectious Diseases Society of America 2
• May decrease effectiveness of hormonal contraceptives, as reported by the American College of Obstetricians and Gynecologists 2
• Live vaccines should be avoided during treatment, according to the Centers for Disease Control and Prevention 4

Monitoring Recommendations

• CBC counts should be monitored weekly for the first month, twice monthly for months 2-3, and monthly for the remainder of the first year, as recommended by the American Society of Hematology 4
• Renal and hepatic profiles should be monitored regularly, according to the National Kidney Foundation 4
• Mycophenolate blood levels may be checked if GI intolerance develops, as reported by the American Gastroenterological Association 4
• Patients should be monitored for signs of infection and malignancy, as noted by the Infectious Diseases Society of America and the American Cancer Society 4

Pre-Treatment Testing Requirements for Mycophenolate Mofetil (MMF)

Essential Laboratory Tests

• Complete blood count (CBC) with differential at baseline to assess for pre-existing cytopenias, as MMF can cause bone marrow suppression, according to the American College of Rheumatology 6
• Comprehensive metabolic panel (CMP) including liver function tests and renal function at baseline, as MMF can cause hepatotoxicity and requires dose adjustment in renal impairment, as recommended by the American College of Rheumatology 6
• Hepatitis B, hepatitis C, and tuberculosis screening should be performed if the patient will be receiving MMF along with JAK inhibitors or other highly immunosuppressive regimens, as suggested by the American College of Rheumatology 6

Clinical Assessments

• Full body skin examination, preferably by a dermatologist, to establish a baseline before initiating therapy, as recommended by the American College of Rheumatology 6

Monitoring Schedule After Initiation

• CBC should be monitored 2-3 weeks after starting and 2-3 weeks after any dose increase, and every 3 months once on a stable dose, according to the American College of Rheumatology 6
• Liver function tests should be monitored 2-3 weeks after starting and 2-3 weeks after any dose increase, and every 3 months once on a stable dose, as recommended by the American College of Rheumatology 6

Common Pitfalls to Avoid

• Not establishing a baseline skin examination, which is important for monitoring potential dermatologic side effects and skin malignancies, as recommended by the American College of Rheumatology 6

Mycophenolate Mofetil and Renal Impairment

Patient Monitoring and Dose Adjustment

• In patients with renal impairment, mycophenolate mofetil requires particular attention as the glucuronide metabolite (MPAG) accumulates significantly—approximately five times normal levels in end-stage renal disease—which may increase susceptibility to various adverse effects including metabolic disturbances, according to Kidney International 7

Mycophenolate Monitoring Guidelines

Introduction to Monitoring

• The American Thoracic Society recommends monitoring CBC counts every 1-3 months indefinitely while patients remain on mycophenolate therapy, with more intensive monitoring during the first year of treatment 8, 9, 10

Initial Monitoring Schedule

• During the first year after initiating mycophenolate therapy, the most intensive monitoring occurs, with weekly CBC counts for the first 4 weeks, twice monthly for months 2-3, and monthly for months 4-12 8, 9, 10

Long-Term Monitoring

• The American Thoracic Society recommends continuing CBC monitoring every 1-3 months for as long as the patient remains on mycophenolate therapy, as hematologic toxicity can occur at any time during treatment 8, 9, 10

Additional Laboratory Monitoring

• Regular monitoring of renal and hepatic profiles is recommended every 1-3 months 8, 11
• Mycophenolic acid (MPA) blood levels are not routinely recommended but may be obtained in specific clinical situations, such as GI intolerance or suspected rejection despite standard dosing 8, 9, 10, 12, 11

Clinical Monitoring for Infections and Complications

• Patients should check their temperature frequently and report fever immediately, as well as report any infection symptoms, neurologic symptoms, respiratory changes, or other concerns 8, 9, 12

Drug Interaction Monitoring

• Live vaccines should be avoided during mycophenolate therapy, and patients should discuss any immunizations with their physician before receiving them 8, 9, 10, 12, 11
• Mycophenolate should not be combined with azathioprine due to increased purine metabolism inhibition 8, 9, 10, 12, 11
• Monitor for interactions with drugs that reduce mycophenolate absorption, such as antacids, iron supplements, and bile acid sequestrants 8, 9